Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo vs. KBP: How a $1.3B deal turned into an international legal fight
Biotech
Regeneron, Sanofi receive 1- to 2-month priority review vouchers
The national priority vouchers position companies including Merck KGaA, Regeneron and Sanofi to complete the review process in one to two months.
Nick Paul Taylor
Oct 17, 2025 8:30am
ESMO: AstraZeneca data ‘validate’ focus on in-house ADCs
Oct 18, 2025 12:55pm
ESMO: Roche wants oral SERD to benefit ‘all comers’
Oct 18, 2025 1:00am
Xoma and Lava buyout cools with lower offer
Oct 17, 2025 2:35pm
Evaxion stock slips on phase 2 cancer vax data
Oct 17, 2025 2:07pm
ESMO: Pfizer sees year-long weight gain in cancer patients
Oct 17, 2025 12:45pm
More News
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Astellas turns down option to license Taysha gene therapy—again
Oct 17, 2025 10:50am
I-Mab unveils new name, strategy, asset and Hong Kong IPO plans
Oct 17, 2025 10:45am
ESMO: BMS believes ADC data allow it to 'stay ahead' of rivals
Oct 17, 2025 10:30am
See more stories